Discovery brings hope of new tailor-made anti-cancer agents

April 21, 2013
Dr Guillaume Lessene and his collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients. Credit: Walter and Eliza Hall Institute, Australia

Scientists at the Walter and Eliza Hall Institute and their collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients.

The development of the compound, called WEHI-539, is an important step towards the design of a potential new anti-cancer agent. WEHI-539 has been designed to bind and block the function of a protein called BCL-XL that normally prevents cells from dying. The death and elimination of in the body is an important safeguard against . But often acquire genetic changes that allow them to bypass cell death, which also reduces the effectiveness of anti-cancer treatments such as chemotherapy.

Cancer cells can become long-lived by producing high levels of BCL-XL protein, and high levels of BCL-XL are also associated with poorer outcomes for patients with lung, stomach, colon and pancreatic cancer.

Dr Guillaume Lessene, Professor Keith Watson and Professor David Huang from the institute's ACRF division, and Dr Peter Czabotar and Professor Peter Colman from the institute's division led the development of WEHI-539 in collaboration with colleagues at , a member of the Roche group. The research is published online today in the journal Nature Chemical Biology.

Dr Lessene said the development of WEHI-539 was an important milestone on the way to creating potential anti- that act to restore cell death by inhibiting BCL-XL. "Although WEHI-539 is not optimised for use in patients, it will be a very valuable tool for researchers to use to dissect how BCL-XL controls cancer cell survival," he said.

WEHI-539 belongs to a class of chemicals called 'BH3-mimetics', which all bind to the same region of BCL-XL or related proteins. Two BH3-mimetics, called navitoclax (ABT-263) and ABT-199/GDC-0199 are currently in clinical trials for the treatment of cancer, particularly those of the blood and lymph glands (leukaemia and lymphoma).

Dr Lessene said WEHI-539 was the product of a sustained research program. "We were very excited to see the team's work culminate in a compound that specifically inhibits BCL-XL," he said. "WEHI-539 is the first compound that our chemists have developed from scratch, using the three-dimensional structure of BCL-XL to build and refine its design."

Explore further: New agents show promise for treating aggressive breast cancers

More information: Paper: DOI: 10.1038/nchembio.1246

Related Stories

New function for the protein Bcl-xL: It prevents bone breakdown

September 14, 2009

In blood cells, the protein Bcl-xL has a well-characterized role in preventing cell death by a process known as apoptosis. However, its function(s) in osteoclasts, cells that slowly breakdown bone (a process known as resorption), ...

New therapeutic target for melanoma identified

April 16, 2009

A protein called Mcl-1 plays a critical role in melanoma cell resistance to a form of apoptosis called anoikis, according to research published this week in Molecular Cancer Research.

Recommended for you

Scientists spin artificial silk from whey protein

January 23, 2017

A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's research light source PETRA III, the scientists could watch just how ...

Scientists develop first catalysed reaction using iron salts

January 20, 2017

Scientists at the University of Huddersfield have developed a new chemical reaction that is catalysed using simple iron salts – an inexpensive, abundant and sustainable alternative to costlier and scarcer metals. The research ...

Chemists cook up new nanomaterial and imaging method

January 20, 2017

A team of chemists led by Northwestern University's William Dichtel has cooked up something big: The scientists created an entirely new type of nanomaterial and watched it form in real time—a chemistry first.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.